This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Schizophrenia, Metabolic Disorders, and Cardiovascular Disease

Daniel E. Casey, MD; Dan W. Haupt, MD; John W. Newcomer, MD; David C. Henderson, MD; Michael J. Sernyak, MD; Michael Davidson, MD; Jean-Pierre Lindenmayer, MD; Steven V. Manoukian, MD, FACC; Mary Ann Banerji, MD; Harold E. Lebovitz, MD; and Charles H. Hennekens, MD

Published: May 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Patients with schizophrenia often have poor health and unhealthy life styles and consequently are at risk for common physical illnesses and increased mortality. In fact, life expectancy for patients with schizophrenia is 57 years for men and 65 years for women, 20% shorter than that for the general population.50,51 While factors contributing to this lower life expectancy for schizophrenia patients include markedly increased risks for suicide as well as infectious and respiratory diseases, cardiovascular mortality is the major contributor to excess mortality in schizophrenia.52‘ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Metabolic Disorder , Side Effects-Medication

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...